Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

General Oncology

Janssen’s Single-Shot COVID-19 Vaccine Gets Emergency Use Authorization

Diana Ernst, RPh

March 1, 2021

The EUA was based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.

Lung Cancer

Pirfenidone Gets Priority Review for Unclassifiable Interstitial Lung Disease

Diana Ernst, RPh

January 21, 2021

The sNDA includes data from a phase 2 trial that evaluated the efficacy and safety of pirfenidone in patients with progressive fibrosing UILD.

General Oncology

Potential Med Errors Prompt FDA Action on Vinca Alkaloid Labeling

Diana Ernst, RPh

January 19, 2021

Chemotherapy agents such as vincristine sulfate injection, vinblastine sulfate injection, and vinorelbine tartrate injection should only be prepared in IV infusion bags.

General Oncology

ACIP: COVID-19 Vaccine Should Be Offered to HCPs, LTC Residents First

Diana Ernst, RPh

December 2, 2020

The recommendation was made based on the number of confirmed COVID-19 cases among these 2 groups, as well as ethical and scientific considerations.

General Oncology

FDA Authorizes COVID-19 Test That Provides Rapid Results at Home

Diana Ernst, RPh

November 20, 2020

This is the first time the Agency has authorized a COVID-19 diagnostic test that provides rapid results at home.

General Oncology

Interim Data Show COVID-19 Vaccine Candidate mRNA-1273 Near 95% Effective

Diana Ernst, RPh

November 16, 2020

The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.

General Oncology

AstraZeneca Pauses COVID-19 Vaccine Trials

Diana Ernst, RPh

September 10, 2020

In a statement, the Company noted that the actions being taken are considered “routine” when an unexplained illness is reported in a clinical trial.

General Oncology

FDA Approves Blood-Based Test as Companion Diagnostic for Multiple Cancer Drugs

Diana Ernst, RPh

August 28, 2020

Using a blood sample, the test is able to analyze more than 300 cancer-associated genes for alterations.

General Oncology

Phase 3 Trial of COVID-19 Vaccine Candidate mRNA-1273 Begins

Diana Ernst, RPh

July 27, 2020

The trial, which is the first to be implemented under Operation Warp Speed, is expected to enroll around 30,000 adults and will be conducted at multiple clinical research sites across the US.

Lung Cancer

Zepzelca Approved for Metastatic Small Cell Lung Cancer

Diana Ernst, RPh

June 17, 2020

The FDA has approved Zepzelca™ (lurbinectedin; Jazz Pharmaceuticals) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

Next post in Lung Cancer